Sign in
CompletedPhase 2

ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection

Key facts

Who runs it
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Where
China5 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
119 people enrolled
Started
31 May 2021
Ended
6 Mar 2024
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Aminolaevulinic acid (500-mg bottle)
  • Aminolaevulinic acid (750-mg bottle)
  • Placebo
Record updated
3 June 2024

Who can take part

Age
18 years to 45 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Premenopausal women, 18-45 years of age
  • Satisfactory the colposcopy examination (cervical transformation zone types: Type 1 or 2) at screening, and CIN2 as verified by cervical biopsy and p16-positivity within the last 3 months
  • Intense desire to retain the cervical structure or function
  • High-risk (including probably/possibly carcinogenic) HPV-DNA (i.e. 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73 or 82) positive within the last 3 months
  • Meet the following conditions: pregnancy test negative; no pregnancy plan during the trial;no sexuality or reliable contraceptive measures taken since last menstruation to the onset of the study, agreeing to adopt reliable contraceptive measures during the study
  • Signed written informed consent

Who cannot take part

  • History of treatment with systemic antivirals (continued for ≥ 14 days) within the last 3 months
  • Atypical glandular cells (AGS) or adenocarcinoma in situ (AIS) on cytology ,or malignant cells on cytology or histology, or other suspicion of either micro-invasive or invasive disease
  • Severe pelvic inflammatory disease, severe cervicitis, or other severe gynaecological infection as per clinical examination
  • Undiagnosed vaginal bleeding within the last 3 months
  • With allergic disease at present; known or suspected porphyria; known allergy to ALA or analogues
  • With serious cardiovascular, neurologic, psychiatric, endocrine, hematological disease; immunocompromised conditions or long-term glucocorticoid or immunosuppressants exposure; patients with malignant tumors within the last 5 years
  • Hepatic or renal functions abnormal (alanine aminotransferase or aspartate transaminase > 3 upper limit of normal [ULN], or total bilirubin > 1.5 ULN, or serum creatinine or blood urea nitrogen > 1.5 ULN)
  • Invasive carcinoma possibility or lesions extending to the vaginal wall
  • Pregnancy or nursing
  • Participation in any clinical studies within the last 30 days
  • Poor compliance or inability to complete the trial
  • Subjects that the investigators judged to be not suitable to participate the study besides above

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Efficacy and Safety of ALA-PDT in patients with cervical intraepithelial neoplasia grade 2 (CIN2) in p16-positivity and high-risk HPV infection.

The 3 groups in the trial

  • ALA A GroupTreatment being tested

    ALA 500mg Group

    Treatment: Aminolaevulinic acid (500-mg bottle)

  • ALA B GroupTreatment being tested

    ALA 750mg Group

    Treatment: Aminolaevulinic acid (750-mg bottle)

  • PlaceboPlacebo, for comparison

    Placebo Group

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase IIc Clinical Trial of ALA-PDT in Patients With Cervical Intraepithelial Neoplasia Grade 2 (CIN2) in p16-positivity and High-risk HPV Infection
Record updated
3 June 2024